Moreover, many GBM driver mutations, such as loss of the tumour suppressor PTEN, or amplification of receptor tyrosine kinase-encoding genes, such as EGFR or platelet-derived growth factor receptor A (PDGFRA), can enhance PI3K−AKT−mTOR signalling. This evidence concerns the gene PTEN and neoplasm.